<DOC>
	<DOCNO>NCT03071354</DOCNO>
	<brief_summary>We propose conduct randomize , control trial β-hydroxy-β-methylbutyrate ( HMB ) supplementation elderly patient ( ≥65 year age ) acute respiratory failure , identify high risk malnutrition ICU-specific nutritional risk score . Patients receive either 3g HMB daily , control , daily day 28 follow randomization ( even discharge ) . We measure functional outcome use standard , validated measure prior discharge .</brief_summary>
	<brief_title>Muscle Function Study</brief_title>
	<detailed_description>We propose conduct randomize , control trial HMB supplementation elderly patient ( ≥65 year age ) acute respiratory failure , identify high risk malnutrition ICU-specific nutritional risk score . Patients receive either 3g HMB daily , control , daily day 28 follow randomization ( even discharge ) . We measure functional outcome use standard , validated measure prior discharge . We hypothesize inexpensive nutrient , HMB , along supportive measure , reduces muscle loss , improve physical muscle function , improve quality life long term follow critical illness .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Paresis</mesh_term>
	<criteria>1 . Patients age ≥65 year . 2 . Acute respiratory failure ( ARF , define expected mechanical ventilation &gt; 72 hour point screen ) 3 . Elevated nutritional risk ( NUTRIC score &gt; 5 see ) . 1 . Over 72 hour ICU admission . 2 . Not expect survive another 48 hour 3 . Lack commitment full , aggressive care 4 . Patients absolute contraindication EN ( obstruction , perforation , high output fistula ) , 5 . Pregnant woman 6 . Prisoners 7 . Known allergy study nutrient 8 . Unable walk prior current illness .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ICU-acquired weakness</keyword>
</DOC>